Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer.

Journal

NEJM evidence
ISSN: 2766-5526
Titre abrégé: NEJM Evid
Pays: United States
ID NLM: 9918317485806676

Informations de publication

Date de publication:
Dec 2022
Historique:
medline: 1 12 2022
pubmed: 1 12 2022
entrez: 6 2 2024
Statut: ppublish

Résumé

Outcomes of Adjuvant Denosumab in Breast CancerIn this long-term report of a prospective, double-blind, placebo-controlled, phase 3 trial of adjuvant aromatase inhibitor in postmenopausal patients with early hormone receptor-positive breast cancer, adjuvant denosumab therapy improved disease-free survival by 3.5 percentage points, bone metastasis-free survival by 2.5 percentage points, and overall survival by 1.0 percentage point at 9 years of follow-up.

Identifiants

DOI: 10.1056/EVIDoa2200162 PMID: 38319865
pubmed: 38319865
doi: 10.1056/EVIDoa2200162
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

EVIDoa2200162

Auteurs

Michael Gnant (M)

Medical University of Vienna, Comprehensive Cancer Center, Vienna.
ABCSG (Austrian Breast & Colorectal Cancer Study Group), Vienna.

Sophie Frantal (S)

ABCSG (Austrian Breast & Colorectal Cancer Study Group), Vienna.

Georg Pfeiler (G)

Department of Gynecology and Gynecological Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna.

Guenther G Steger (GG)

Department of Internal Medicine I, Medical University of Vienna, Vienna.

Daniel Egle (D)

Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria.

Richard Greil (R)

Department of Internal Medicine III, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute, Center for Clinical Cancer and Immunology Trials; Cancer Cluster Salzburg, Salzburg, Austria.

Florian Fitzal (F)

Department of General Surgery and Breast Health Center of the Comprehensive Cancer Center, Medical University of Vienna, Vienna.

Viktor Wette (V)

Breast Center Carinthia, St. Veit, Austria.

Marija Balic (M)

Division of Oncology, Department of Internal Medicine, and Comprehensive Cancer Center, Medical University of Graz, Graz, Austria.

Ferdinand Haslbauer (F)

Department of Internal Medicine, Salzkammergut Klinikum Hospital Vöcklabruck, Vöcklabruck, Austria.

Elisabeth Melbinger-Zeinitzer (E)

Department of Surgery, Hospital Wolfsberg, Wolfsberg, Austria.

Vesna Bjelic-Radisic (V)

Department of Gynecology and Obstetrics, Medical University of Graz, Graz, Austria.
Breast Unit, Helios University Hospital Wuppertal, Wuppertal Germany, University Witten/Herdecke, Germany.

Silvia Artner-Matuschek (S)

Department of Gynecology, Hanusch Hospital Vienna, Vienna.

Franz Kainberger (F)

Division of Neuro- and Musculoskeletal Radiology, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna.

Magdalena Ritter (M)

Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria.

Gabriel Rinnerthaler (G)

Department of Internal Medicine III, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute, Center for Clinical Cancer and Immunology Trials; Cancer Cluster Salzburg, Salzburg, Austria.

Paul Sevelda (P)

Department of Gynecology, Karl Landsteiner Institute for Gynecologic Oncology and Senology, Hospital Hietzing, Vienna.

Jonas Bergh (J)

Department of Oncology-Pathology, Cancer Research Karolinska Institutet, Stockholm.

Stephanie Kacerovsky-Strobl (S)

Department of General Surgery and Breast Health Center of the Comprehensive Cancer Center, Medical University of Vienna, Vienna.
Breast Health Center, St. Francis Hospital Vienna, Vienna.

Christoph Suppan (C)

Division of Oncology, Department of Internal Medicine, and Comprehensive Cancer Center, Medical University of Graz, Graz, Austria.

Christine Brunner (C)

Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria.

Christine Deutschmann (C)

Department of Gynecology and Gynecological Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna.

Simon P Gampenrieder (SP)

Department of Internal Medicine III, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute, Center for Clinical Cancer and Immunology Trials; Cancer Cluster Salzburg, Salzburg, Austria.

Hannes Fohler (H)

ABCSG (Austrian Breast & Colorectal Cancer Study Group), Vienna.

Raimund Jakesz (R)

Department of General Surgery and Breast Health Center of the Comprehensive Cancer Center, Medical University of Vienna, Vienna.

Christian Fesl (C)

ABCSG (Austrian Breast & Colorectal Cancer Study Group), Vienna.

Christian Singer (C)

Department of Gynecology and Gynecological Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna.

Classifications MeSH